A number of therapeutic options are available for the treatment of advanced kidney cancer, including targeted therapy, immunotherapy, and nephrectomy. Choice of therapy for advanced kidney cancer is guided by risk stratification. Immunotherapy combinations are generally superior to vascular endothelial growth factor -based monotherapy, and overall survival rates continue to increase substantially. With new systemic therapy options, additional improvements have been noted in durable responses to treatment and in quality of life. Nephrectomy remains an important consideration in selected patients, particularly those with minimal burden of metastatic disease. Managing the adverse events of treatment of advanced kidney cancer requires close attention and multidisciplinary collaboration.
Disclosures: Dr. LaGrange has disclosed that he receives grant/research support from Boston Scientific, a consulting fee from Integer, and is a scientific advisor for Manzanita Pharmaceuticals. Dr. Michaelson has disclosed that he is a scientific advisor for Eisai Inc, Exelixis Inc, and Pfizer Inc. Ms. Tetzlaff has disclosed that she has no relevant relationships.
Correspondence: Chad A. LaGrange, MD, University of Nebraska, 984110 Nebraska Medical Center, Omaha, NE 68198. Email: email@example.com; M. Dror Michaelson, MD, PhD, Massachusetts General Hospital, 55 Fruit Street, Yawkey 7E, Boston, MA 02114. Email: firstname.lastname@example.org; and Colleen H. Tetzlaff, MHS, PA-C, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Email: email@example.com
MotzerR, RiniB, McDermottDF, Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomized, controlled phase3 trial. Lancet Oncol2019;20:1370–1385.
MotzerR, RiniB, McDermottDF, Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomized, controlled phase3 trial. Lancet Oncol 2019;20:1370–1385.10.1016/S1470-2045(19)30413-9)| false